OncoSil Medical (ASX: OSL) is celebrating the commencement of the first Initial commercial treatments involving the OncoSil medical device for the treatment of Pancreatic cancer in Greece have just commenced at renowned hospital in Athens.
These treatments see Greece become the third European country – after Italy and Spain – where commercial treatments utilising the OncoSil device have been completed.
OncoSil Medical has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long‐term survival.
The OncoSil device delivers a targeted intratumoural placement of Phosphorous‐32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine‐based chemotherapy.
The device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil device, which can be marketed in the European Union, United Kingdom.
While clinical trials involving the OncoSil device continue to occur, the company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.
OncoSil Medical CEO and Managing Director Nigel Lange said these treatments represent delivery of another milestone in the commercialisation strategy for this innovative device, which is intended for the treatment of locally advanced unresectable pancreatic cancer, in combination with gemcitabine‐based chemotherapy.
In cooperation with our Greek partners Mediray, these treatments see Greece becoming the third European country – after Italy and Spain – where commercial treatments utilising the OncoSil device have been ongoing.
Another milestone achieved in the OncoSil device’s commercialisation strategy
The first commercial treatments on Greece‐based patients with locally advanced pancreatic cancer represent another step in OncoSil’s plans to penetrate its target European market, which extends across multiple countries. As these treatments are commercial rather than clinical trial related, they additionally represent a clear positive signal for OncoSil’s long‐term sustainability.
These treatments, which involved two patients, were undertaken at the Agios Savvas Hospital, located in Athens. This facility specialises in the treatment of all solid tumors, with a primary emphasis on breast, lung, digestive, pancreatic and melanoma cancers.
It is good to see the continued progress being made in our concerted efforts to commercialise the OncoSil device. The just‐completed initial commercial treatments in Greece at the Agios Savvas Hospital means that our innovative OncoSil device has now been utilised in commercial treatments in three European countries – and we remain confident that other countries across Western Europe will join this list,” Mr Lange said
